Radiation recall secondary to adjuvant docetaxel after balloon-catheter based accelerated partial breast irradiation

Nathan W. Wong, William W. Wong, Nina J. Karlin, Richard J. Gray

Research output: Contribution to journalArticle

Abstract

For early stage breast cancer, wide local excision and post-operative whole breast irradiation is a standard treatment. If adjuvant chemotherapy is recommended, radiation is usually given after completion of chemotherapy. In recent years, accelerated partial breast irradiation (APBI) with balloon-cathetered based brachytherapy has become an option for selected patients. For these patients, adjuvant chemotherapy would have to be administered after radiation. The sequence of treatment with radiation followed by chemotherapy results in increased risk of radiation recall reaction (RRD) in these patients. Docetaxel is becoming a more commonly used drug as adjuvant treatment for breast cancer. Here we report a case of docetaxel induced RRD after APBI with balloon-cathetered based brachytherapy. Such reaction would have an adverse impact on the cosmetic outcome and quality of life of the patient. For patients who develop an intense skin reaction after the administration of docetaxel following APBI, RRD should be considered in the differential diagnosis.

Original languageEnglish (US)
Pages (from-to)253-255
Number of pages3
JournalRadiography
Volume16
Issue number3
DOIs
StatePublished - Aug 1 2010

Keywords

  • Accelerated partial breast irradiation
  • Breast brachytherapy
  • Docetaxel
  • Mammosite
  • Radiation recall dermatitis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Radiation recall secondary to adjuvant docetaxel after balloon-catheter based accelerated partial breast irradiation'. Together they form a unique fingerprint.

  • Cite this